Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes

British Journal of Dermatology

Volumn 137, Issue 1, 1997, Pages 65-75

  Nibbering, P H ^a   Thio, B ^a   Bezemer, A C ^a   Beijersbergen, R L ^a   Zomerdijk, T P L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRUG METABOLITE; FUMADERM; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HISTONE H4; MESACONIC ACID ESTER; PERTUSSIS TOXIN; PHOSPHOLIPASE D; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; STAUROSPORINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL MEMBRANE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 0030812364     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb03702.x     Document Type: Article

References (45)

1. Nieboer C, Hoop D de, Loenen AC van et al. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989: 20: 601-8.
2. Nugteren-Huying WH, Schroeff JG van der, Suurmond D. Fumaric acid therapy for psoriasis. A randomized. double blind. placebo-controlled study. J Am Acad Dermatol 1990; 22: 311-12.
3. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol 1994: 30: 977-81.
4. Thio HB, Schroeff JG van der, Nugteren-Huying HW et al. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 35-40.
5. Dijk E van. Fumaarzuur voor de behandeling van patiënten met psoriasis. Ned Tijdschr Geneesk 1985; 129: 485-6.
6. Bacharach-Buhles M, Pawlak F, Matthes U et al. Fumaric acid esters (FAEs) suppress CD15- and ODP 4-positive cells in psoriasis. Acta Derm Venereol (Stockh) 1994; 186: 79-82.
7. Nibbering PH, Thio HB, Zomerdijk TPL et al. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 1993; 100: 1-5.
8. Thio HB, Zomerdijk TPL, Oudshoorn C et al. Fumarates evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes and SVK-14 cells. Br J Dermatol 1994; 131: 856-61.
9. Jong R de, Bezemer AC, Pouw-Kraan T van de et al. Selective stimulation of T-helper 2 type cytokine responses by the antipsoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-74.
10. Novak TJ, Rothenberg EV. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci USA 1990; 87: 9353-7.
11. Haraguchi S, Good RA, James-Yarish M et al. Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. Proc Natl Acad Sci USA 1995: 92: 3611-15.
12. Ockenfels HM, Nussbaum G, Schultewolter T et al. Cyclosporin A. FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. Arch Dermatol Res 1995; 287: 304-9.
13. Iyengar R. Gating by cyclic AMP: Expanded role for an old signalling pathway. Science 1996; 271: 461-3.
14. Auwerx J, Sassone-Corsi P. IP-I: a dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation. Cell 1991; 64: 983-93.
15. Tsurata L, Lee MJ, Masuda ES et al. Cyclic AMP inhibits expression of the IL-2 gene through the nuclear factor of activated T cells (NF-AT) site and transfection of NF-AT cDNA5 abrogates the sensitivity of EL-4 cells to cAMP. J Immunol 1995: 154: 5255-64.
16. Voorhees JJ, Duell M. Psoriasis as a possible defect of adenylyl cyclase cyclic AMP cascade. Arch Dermatol 1971: 104: 352-8.
17. Brion DE, Raynaud F, Plet A et al. Deficiency of cyclic AMP-dependent protein kinases in human psoriasis. Proc Natl Acad Sci USA 1986; 83: 5272-6.
18. Horn F, Marks F, Fisher GJ et al. Decreased protein kinase C activity in psoriatic versus normal epidermis. J Invest Dermatol 1987: 88: 220-2.
19. Kerckhof PCM van de. Erp PKJ van. Calmodulin levels are grossly elevated in the psoriatic lesion. Br J Dermatol 1983; 108: 217-18.
20. Pike MC, Lee CS, Elder JT et al. Increased phosphatidylinositol kinase activity in psoriatic epidermis. J Invest Dermatol 1989; 92: 791-7.
21. Raynaud R, Enjolas O, Donnadieu M et al. A cAMP binding abnormality in psoriasis. Lancet 1989: 27: 1153-6.
22. Geerdink JPM, Bergers M, Erp PEJ van et al. Cyclic AMP is decreased in mononuclear leucocytes from psoriasis patients. Br J Dermatol 1980; 103: 107-8.
23. Hollenberg M. Structure-activity relationship for transmembrane signalling: the receptor's turn. FASEB J 1991; 5: 178-86.
24. Böyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21: S97: 7-9.
25. ++ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-7.
26. Zomerdijk TPL, Nibbering PH, Bezemer AC et al. A new competition binding assay for determination of the cAMP content of human leukocytes. Biochem Biophys Res Commun 1991; 178: 980-4.
27. Nibbering PH, Zomerdijk TPL, Corsél-van Tilburg AJ et al. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J Immunol Methods 1990; 129: 143-5.
28. Nibbering PH, Zomerdijk TPL, Haastert PJM van et al. A competition binding assay for determination of the inositol (1,4,5)-triphosphate content of human leukocytes. Biochem Biophys Res Commun 1990; 170: 755-62.
29. Snoek GT, Boonstra J, Ponec M et al. Phorbol ester binding and protein kinase C activity in normal and transformed human keratinocytes. Exp Cell Res 1987; 172: 146-57.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
31. Kessels GCR, Gervais A, Lew PD et al. The chymotrypsin inhibitor carbobenzyloxy-leucine-tyrosine-chloromethylketone interferes with phospholiphase D activation induced by formyl-methionyl-leucyl-phenylalanine in human neutrophils. J Biol Chem 1991; 266: 15870-5.
32. Zheng L, Nibbering PH, Zomerdijk TPL et al. Protein tyrosine kinase activity is essential for Fcγ receptor-mediated intracellular killing of Staphylococcus aureus by human monocytes. Infect Immun 1994; 62: 4296-303.
33. Huang CK, Laramee GR. Stimulation of a histone H4 protein kinase in Triton X-100 lysates of rabbit peritoneal neutrophils pretreated with chemotactic factors: effect of leukotriene B4 and cytochalasin B. J Leukocyte Biol 1991; 49: 158-62.
34. Wilde MW, Carlson KE, Manning DR et al. Chemoattractant-stimulated GTPase activity is decreased on membranes from polymorphonuclear leukocytes incubated in chemoattractant. J Biol Chem 1989; 264: 190-6.
35. Moser B, Schumacher C, Scharneer V von et al. Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 1991; 266: 10666-71.
36. 2+/calmodulin sensitivity may be common to all forms of neural adenylate cyclase. Proc Natl Acad Sci USA 1989; 86: 9564-73.
37. Berridge MJ. The molecular basis of communication within the cell. Sci Am 1985; 253: 124-34.
38. Snyderman R, Uhing RJ. Phagocytic cells: stimulus-response coupling mechanisms. In: Inflammation: Basic Principles and Clinical Correlates (Gallin JI, Goldstein IM, Snyderman R, eds). New York: Raven Press, 1989: 309-23.
39. Marwan W, Schäfer W, Oesterhelt D. Signal transduction in halobacterium depends on fumarate. EMBO J 1990; 9: 355-62.
40. Didsbury JR, Uhing RJ, Thomhave ED et al. Receptor class desensitization of leukocyte chemoattractant receptors. Proc Natl Acad Sci USA 1991; 88: 11564-8.
41. Tomhave ED, Richardson RM, Didsbury JR et al. Cross-desensitization of receptors for peptide chemoattractants. J Immunol 1994; 153: 3267-75.
42. Dohlman HG, Caron MG, Lefkowitz RJ. Model systems for the study of seven-transmembrane segment receptors. Annu Rev Boichem 1991; 60: 653-88.
43. Atlante A, Passarella P, Gianattasio S et al. Fumarate permeation in rat liver mitochondria: fumarate/phosphate translocators. Biophys Biochem Res Commun 1985: 132: 8-18.
44. 2+ release and its modulation by cyclic ADP-ribose. Trends Pharmacol Sci 1992; 13: 304-6.
45. Gosh TK, Mullaney JM, Tarazi FI et al. GTP activated communication between distinct inositol 1,4,5-triphosphate-sensitive and -insensitive calcium pools. Nature 1989; 340: 236-9.